ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2132 entries already.
Within the competitive CDMO market, Richter-Helm has developed into a highly valued partner when it comes to the manufacturing of biopharmaceuticals. Richter-Helm is well recognised by pharmaceutical companies, including Big Pharma, as a professional partner offering flexible CDMO solutions from gene to product, all from one source, including consultancy services. This makes Richter-Helm one of the key players in CDMO business.
SpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease.
Antiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development
Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
On Sunday, the World Health Summit with more than 300 speakers officially kicked off in Berlin. The three day event focuses on climate change and health, pandemic prevention, and digital technologies.
Dutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01.
A method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers report.
Try TSKgel UP-SW columns for SEC analysis of biomolecules risk-free for 30 days
A well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.
Belgian fibrosis specialist Agomab Therapeutics NV has raised US$100m to advance development of its pipeline.